tremelimumab at activation barrier; commitment threshold, addressing setpoint loss
tremelimumab (ctla4 brake release) acts at the activation barrier; commitment threshold step of the cancer-immunity cycle. The failure mode is setpoint loss: homeostat loses memory of its setpoint. System drifts without correction.
What this is
The Living Scorecard is Encounter's open record of structural predictions. Each hypothesis names a candidate intervention, where in the cycle it is predicted to act, the failure mode it is predicted to address, and the evidence available when the prediction was made.
Predictions are locked with timestamps before they can be tested. Encounter generates them daily, many more than any one person can chase, so the field can see what the framework claims structurally, ahead of the data. Some will hold. Some will be refuted. Both stay on the page. The point is that each prediction is committed before the answer is known, so the data that arrives later can confirm or refute it.
Structural argument
At the activation barrier; commitment threshold step of the cancer-immunity cycle (capacitor regime, position P4), tremelimumab acts via ctla4 brake release. The failure mode is setpoint loss: homeostat loses memory of its setpoint. System drifts without correction. The intervention's regime-type class lines up with the position's regime, and failure_setpoint_loss belongs to that regime's failure set.
rule_r13(required) — Combinatorial candidate is grounded in R13's position-to-state table, which determines which interventions are structurally addressable at which positions.
Substrate
- Domain
- domain_cellular_biology
- Cycle
- cycle_l4_canonical
- Position(s)
- position_p4
- Failure modes
- failure_setpoint_loss
Evidence at generation
"tremelimumab" AND "cancer immunotherapy"
- PMID 29778737
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
- PMID 39447408
A comprehensive review of immune checkpoint inhibitors for cancer treatment.
- PMID 39514829
Immune Checkpoint Inhibitor Myopathy: The Double-Edged Sword of Cancer Immunotherapy.
- PMID 37726418
Biomarkers for immunotherapy of hepatocellular carcinoma.
- PMID 37596898
Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
Targets: CHEMBL2364164
inhibitor
tremelimumab cancer immunotherapy
- NCT01034787
Uveal Melanoma
Primary: Progression-free survival at 6 months after initiation of CP-675,206
- NCT03132467
Anatomic Stage II Breast Cancer AJCC v8
Primary: Feasibility of Enrolling 15 Patients Within 2 Years
- NCT03426657
Locally Advanced Head and Neck Squamous Cell Carcinoma
Primary: Assessment of the number of participants receiving the protocol treatment until cycle 6 of antibody treatment
- NCT06058663
Locally Advanced Intrahepatic Cholangiocarcinoma
Primary: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) (Cohort 1)
- NCT02535078
Malignant Melanoma
Primary: Phase 2: Objective Response Rate (ORR)
Status timeline
- Draft2026-05-30T11:27:14Z
Generated by combinatorial walker (v0.1.1; verb_target-aware, sub-regime failures). Awaiting operator review for the daily top-5 batch.
by system